Sponsors (2)
The bill clarifies and standardizes patent-eligibility rules—reducing judicial uncertainty and improving protection for many inventions (especially modified biotech and clearly machine-implemented innovations)—but in doing so it shifts legal battles, may broaden patents in ways that raise costs for consumers and healthcare, and reduces certain protections startups relied on for software and business-method innovations.
Researchers, inventors, and small biotech/tech companies gain clearer, broader patent-eligibility rules and guidance that make it easier to evaluate and pursue patent protection, likely increasing innovation and investment for affected technologies.
Patent examiners, applicants, and courts receive explicit statutory rules (including removal of certain judicial exceptions) that reduce uncertainty, produce more consistent examination/decisionmaking, and give clearer bases to grant or reject claims.
Biotech innovators (those who modify, purify, or enrich natural materials) can obtain patent protection on altered or isolated genes and materials used in inventions, strengthening commercialization prospects for many life-science discoveries.
Consumers and businesses could face higher costs because broader eligibility may allow more patents on business or technical methods and drive licensing fees or royalties across many products and services.
Software startups, tech workers, and small firms risk losing or never obtaining patent protection for business-method or software-based innovations due to explicit exclusions and tighter limits on generic computer implementations, reducing investment incentives in that sector.
Eliminating certain judicially-developed eligibility tests and barring consideration of conventionality/prior art in eligibility determinations is likely to shift disputes into other validity grounds (novelty, nonobviousness, enablement), increasing complexity and overall litigation costs.
Based on analysis of 4 sections of legislative text.
Replaces judge-made patent-eligibility exceptions with a statutory rule that most useful inventions are eligible while listing narrow exclusions (math, mental steps, unmodified genes/materials, business/social processes).
Introduced May 1, 2025 by Kevin Kiley · Last progress May 1, 2025
Rewrites the federal test for what kinds of inventions can be patented by declaring that most useful processes, machines, manufactures, and compositions of matter (and useful improvements) are eligible for patent protection while listing specific narrow categories that remain ineligible. It removes the set of judge-made “exceptions” that courts have used to reject patents, clarifies that novelty, nonobviousness, and written-description requirements remain separate patentability tests, and directs courts to assess eligibility by looking at the claimed invention as a whole. The law also defines “useful” with a practical-utility standard, excludes purely mental steps, certain standalone mathematical formulas, unmodified human genes and natural materials as they exist in nature, and substantially economic/financial/business/social/cultural/artistic processes. It limits attempts to make ineligible subject matter patentable by merely adding pre- or post-solution computer or machine steps unless the machine is actually necessary to perform the invention in practice, and preserves existing doctrine on obviousness-type double patenting.